Literature DB >> 15294323

Real-time allele-specific amplification for sensitive detection of the BRAF mutation V600E.

Anne Jarry1, Damien Masson, Elisabeth Cassagnau, Sigrid Parois, Christian Laboisse, Marc G Denis.   

Abstract

BRAF is a cytoplasmic serine/threonine kinase in the MAPK pathway that transduces signals from RAS family members to MEK1/2. Mutations in the BRAF gene have been described in the majority of cutaneous melanomas, papillary thyroid carcinoma and to a lesser extent in other cancers. The predominant mutation reported is a single transversion in exon 15 (T1799A). We designed a real-time allele-specific PCR to detect this mutation. This assay allowed us to detect this alteration in samples containing 2% of cells harboring this mutation, which is equivalent to 1% mutated DNA, assuming heterozygosity for the allele. Using this assay, we then tested 44 human primary colorectal tumors. We found the V600E mutation in four samples (9.1%). Analysis of DNA extracted from paraffin-embedded sections gave similar results, indicating that archived tissues can also be analyzed using this assay. The advantages of this method include: (1) rapidity; (2) sensitivity; (3) ease; (4) large throughput; (5) low cost and (6) the small quantities of DNA needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15294323     DOI: 10.1016/j.mcp.2004.05.004

Source DB:  PubMed          Journal:  Mol Cell Probes        ISSN: 0890-8508            Impact factor:   2.365


  28 in total

1.  Is a single BRAF wild-type test sufficient to exclude melanoma patients from vemurafenib therapy?

Authors:  Mélanie Saint-Jean; Gaëlle Quéreux; Jean-Michel Nguyen; Lucie Peuvrel; Anabelle Brocard; Audrey Vallée; Anne-Chantal Knol; Amir Khammari; Marc G Denis; Brigitte Dréno
Journal:  J Invest Dermatol       Date:  2013-09-11       Impact factor: 8.551

2.  Application of genomic principles to pharmacotherapy of cancer.

Authors:  Christopher L Farrell; Nancy G Pedigo; Amy R Messersmith
Journal:  Am J Pharm Educ       Date:  2014-04-17       Impact factor: 2.047

3.  A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.

Authors:  Claudia Martinuzzi; Lorenza Pastorino; Virginia Andreotti; Anna Garuti; Michele Minuto; Roberto Fiocca; Giovanna Bianchi-Scarrà; Paola Ghiorzo; Federica Grillo; Luca Mastracci
Journal:  Endocrine       Date:  2015-08-22       Impact factor: 3.633

4.  The mechanism of the adsorption of dsDNA on citrate-stabilized gold nanoparticles and a colorimetric and visual method for detecting the V600E point mutation of the BRAF gene.

Authors:  Zhen Liu; Menik Hettihewa; Yang Shu; Chunqiong Zhou; Qian Wan; Lihong Liu
Journal:  Mikrochim Acta       Date:  2018-03-27       Impact factor: 5.833

5.  A Sensitive Peptide Nucleic Acid Probe Assay for Detection of BRAF V600 Mutations in Melanoma.

Authors:  Tai-Long Chen; John Wen-Cheng Chang; Jia-Juan Hsieh; Hsin-Yi Cheng; Chiuan-Chian Chiou
Journal:  Cancer Genomics Proteomics       Date:  2016 09-10       Impact factor: 4.069

6.  Evaluation of high-resolution melting analysis as a diagnostic tool to detect the BRAF V600E mutation in colorectal tumors.

Authors:  Martin Pichler; Marija Balic; Elke Stadelmeyer; Christoph Ausch; Martina Wild; Christian Guelly; Thomas Bauernhofer; Hellmut Samonigg; Gerald Hoefler; Nadia Dandachi
Journal:  J Mol Diagn       Date:  2009-02-12       Impact factor: 5.568

7.  Molecular biomarker analyses using circulating tumor cells.

Authors:  Elizabeth A Punnoose; Siminder K Atwal; Jill M Spoerke; Heidi Savage; Ajay Pandita; Ru-Fang Yeh; Andrea Pirzkall; Bernard M Fine; Lukas C Amler; Daniel S Chen; Mark R Lackner
Journal:  PLoS One       Date:  2010-09-08       Impact factor: 3.240

Review 8.  Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.

Authors:  Martin Frank; Thomas Mittendorf
Journal:  Pharmacoeconomics       Date:  2013-03       Impact factor: 4.981

9.  Reappraisal of the so-called 'villous tumours' of the rectosigmoid, based on histological, immunohistochemical and genotypic features.

Authors:  Laure Droy-Dupré; Sébastien Küry; Emmanuel Coron; Stéphane Bézieau; Christian L Laboisse; Jean-François Mosnier
Journal:  United European Gastroenterol J       Date:  2014-08       Impact factor: 4.623

10.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts.

Authors:  Alain R Thierry; Florent Mouliere; Celine Gongora; Jeremy Ollier; Bruno Robert; Marc Ychou; Maguy Del Rio; Franck Molina
Journal:  Nucleic Acids Res       Date:  2010-05-21       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.